• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Theravance Biopharma, Inc. - Ordinary Shares (NQ:TBPH)

    19.66 +0.23 (+1.18%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Theravance Biopharma, Inc. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Vistance Networks Stock Up 250%. Here's Why a $40 Million Position Signals a Post-Divestiture Bet ↗
    Vistance Networks delivers connectivity and network solutions for telecom, data centers, and enterprise clients worldwide. 
    Via The Motley Fool
    News headline image
    Array Stock Down 25%, But This $17.3 Million Buy Signals Confidence Amid Big Revenue Growth ↗
    Array Digital Infrastructure delivers wireless services and device sales to consumers, businesses, and government clients nationwide. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Enviri Stock Up 120% as $43 Million Buy Makes It a Top Holding in This Portfolio ↗
    Enviri delivers environmental and specialty waste solutions for industrial clients through long-term contracts and value-added products. 
    Via The Motley Fool
    Topics Regulatory Compliance
    Theravance Biopharma Inc (NASDAQ:TBPH) Shows Strong Technical and Fundamental Momentum ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 10, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For May 8, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For February 26, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For November 12, 2024 ↗
     
    Via Benzinga
    News headline image
    Integer Stock Down 38%, but One Fund Just Bet $40 Million on a Turnaround ↗
    Integer Holdings supplies medical device components and finished products to major OEMs in cardiac, neuro, and surgical markets. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Irenic Dumps Most Papa John's Shares ↗
    Papa John's International runs a global pizza network, earning revenue from both direct restaurant operations and franchise royalties. 
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Unveiling 4 Analyst Insights On Theravance Biopharma ↗
     
    Via Benzinga
    These stocks that are showing activity before the opening bell on Friday. ↗
    Via Chartmill
    These stocks that are showing activity before the opening bell on Tuesday. ↗
    Via Chartmill
    News headline image
    Millrose Properties Stock Has Surged 48% Since February Debut — So Why Did One Investor Sell a $23 Million Stake? ↗
    A newly public real-estate platform is putting up numbers that look far more seasoned than its age. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why One Investor Bought $67.5 Million in Array Digital Infrastructure Stock ↗
    One fund just made a bold bet on a telecom stock undergoing a big transformation 
    Via The Motley Fool
    News headline image
    Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge ↗
    This fund just doubled down on a stock that’s suddenly delivering the earnings momentum it’s promised for years. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs ↗
    A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors. 
    Via The Motley Fool
    News headline image
    Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗
    Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
    Via Chartmill
    News headline image
    Here's Why Shares in Theravance Biopharma Exploded Today ↗
    The company is making excellent progress on all its strategic goals. 
    Via The Motley Fool
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Theravance Biopharma Inc (NASDAQ:TBPH) Reports Q3 2025 Earnings Beat Amid Muted Market Reaction ↗
    Theravance Biopharma (TBPH) reported Q3 2025 results, beating EPS estimates with a profit of $0.04. Revenue was slightly below forecasts. Lead drug YUPELRI achieved record sales. 
    Via Chartmill
    Topics Earnings
    News headline image
    PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy
    From Theravance Biopharma
    Via Business Wire
    News headline image
    This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
     
    Via Benzinga
    News headline image
    Theravance Sales Jump 83 Percent ↗
    Via The Motley Fool
    News headline image
    Theravance Biopharma Inc (NASDAQ:TBPH) Misses Q2 2025 Revenue and EPS Estimates Amid Mixed Market Reaction ↗
    Theravance Biopharma (TBPH) Q2 2025 earnings missed revenue and EPS estimates, but stock rose 3.1% after-hours. Focus remains on YUPELRI and Ampreloxetine pipeline. 
    Via Chartmill
    Topics Earnings
    News headline image
    This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For August 12, 2025 ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.